Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer : says studies show COVID-19 vaccine over 90% effective in kids 5-11

10/22/2021 | 11:21am EST

Studies show that child-sized doses of Pfizer's COVID-19 vaccine are safe and better than 90% effective in kids between 5 and 11 years old, the pharma company said Friday as federal regulators consider authorizing the shots for younger children.

The Food and Drug Administration posted the data Friday, which said the smaller vaccine doses proved to be almost 91% effective in preventing symptomatic COVID-19 in kids 5-11.

The study involved nearly 2,300 children in that age range -- many of whom received two doses of the vaccine three weeks apart. The others received placebo doses.

The dose given to the younger children, 10 micrograms, is a third of the amount given to adults and children 12 to 16 years old. Pfizer said the smaller dose would minimize side effects but still activate a strong immune response.

Pfizer's vaccine is already being administered in children 12 to 16 years old. If its lower dose is approved, the vaccine would be the first to be authorized for children as young as 5. File Photo by John Angelillo/UPI

"Two primary doses of the vaccine given three weeks apart in 5 to 11 years of age have shown a favorable safety and tolerability profile, robust immune responses against all variants of concern and high [effectiveness] against symptomatic COVID-19 in a period where the Delta variant was predominant," Pfizer's 82-page report said.

"Given all the [data], the benefits of the Pfizer-BioNTech COVID-19 vaccine ... in children 5 to 11 years of age outweigh the known or potential risks."

The FDA was expected to post an independent review of the Pfizer data later Friday.

The agency's Vaccines and Related Biological Products Advisory Committee will meet on Tuesday to weigh including children 5-11 in its emergency use authorization for Pfizer's coronavirus vaccine.

If the panel approves lower doses for younger children, the FDA and Centers for Disease Control and Prevention would also need to sign off on them. If that happens, children in the lower age range could begin to receive the vaccine next month.

The data showed that the antibody response in children with the lower dosage were comparable to the immune response seen in adults who'd received the vaccine.

Pfizer's vaccine is already being administered in children 12 to 16 years old. If its lower dose is approved, the vaccine would be the first to be authorized for children as young as 5.

Copyright 2021 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source Health News - Business

All news about PFIZER, INC.
01:21aUK jabs deal to 'future-proof' immunisation
AQ
12/02Pfizer Taps Amazon Web Services To Boost Clinical Manufacturing Via Cloud-Based Solutio..
MT
12/02Pfizer-BioNTech, Moderna's COVID-19 Jabs Offer Best Immunity Boost, UK Study Says
MT
12/02U.S. administers 464.4 mln doses of COVID-19 vaccines - CDC
RE
12/02Wall Street ends higher in robust rebound from Omicron-driven rout
RE
12/02DOJ, SEC Charge Former Immunomedics Finance Chief With Insider Trading
DJ
12/02What COVID-19 vaccine and drug makers have to say about Omicron
RE
12/02Amazon Web Services, Pfizer Collaborate to Improve New Medicine Development, Distributi..
MT
12/02ViiV - FORTY YEARS ON FROM THE START OF THE HIV EPIDEMIC, NEW DATA REVEALS PEOPLE LIVIN..
AQ
12/02Covid-19 - Mobile Vaccination Teams Deployed to Weekly Markets, Inland Regions
AQ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 517 M - -
Net income 2021 21 354 M - -
Net Debt 2021 27 873 M - -
P/E ratio 2021 13,6x
Yield 2021 2,97%
Capitalization 298 B 298 B -
EV / Sales 2021 3,99x
EV / Sales 2022 3,76x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 53,04 $
Average target price 49,58 $
Spread / Average Target -6,53%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Susan Silbermann President & General Manager-Pfizer Vaccines
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.44.09%297 706
JOHNSON & JOHNSON-0.18%413 555
ROCHE HOLDING AG17.62%341 509
NOVO NORDISK A/S64.51%243 534
ELI LILLY AND COMPANY47.55%224 726
ABBVIE INC.8.18%206 612